Fezolinetant

Drug Profile

Fezolinetant

Alternative Names: ESN-364

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Euroscreen
  • Developer Ogeda
  • Class Pyrazines; Small molecules; Triazoles
  • Mechanism of Action Gonadal steroid hormone modulators; Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hot flashes; Polycystic ovary syndrome; Uterine leiomyoma
  • Preclinical Weight gain
  • No development reported Benign prostatic hyperplasia; Endometriosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Benign-prostatic-hyperplasia(In volunteers) in Europe (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Endometriosis(In volunteers) in Europe (PO, Capsule)
  • 26 Jun 2017 Phase-II clinical trials in Hot flashes (In the elderly, In adults) in USA (PO) (NCT03192176)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top